RxDoctor Payments Data

Zubair Shah, MD

Advanced Heart Failure and Transplant Cardiology · Kansas City, KSNPI 1386942126

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $276,627 of the $387,311 with a category attached, or 71.4%. Alnylam Pharmaceuticals Inc. accounts for 63.2% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $109,269, 6.2 times the $17,510 reported in 2019.

$387,311in general payments, 2019–2025

Across 716 payments — averaging $540.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$245K
  • AstraZeneca$97K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$29K
  • Pfizer$6K
  • Akcea Therapeutics, Inc.$4K
  • Abbott$3K
  • plus $3K from 23 others
$1,927,201in research payments, 2019–2025

Across 550 payments — averaging $3504.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$1.8M
  • Abbott$92K
  • Ionis Pharmaceuticals, Inc.$38K
  • Procyrion, Inc.$32K
  • AstraZeneca$10K
  • Bayer$3K

What the payments were for

  • Consulting fees$60,95216%
  • Speaking & faculty fees$276,62771%
  • Travel & lodging$32,4488%
  • Food & beverage$17,1424%
  • Education$1420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$154,908
Medicare patients
507
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis958$21,073,188
WainuaEplontersen Sodium35$1,372,360
EntrestoSacubitril/Valsartan405$471,395
JardianceEmpagliflozin337$398,076
EliquisApixaban299$295,500
FarxigaDapagliflozin Propanediol286$285,700
OzempicSemaglutide111$108,935
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres18$74,502
MounjaroTirzepatide59$59,403
XareltoRivaroxaban44$53,781
Repatha SureclickEvolocumab24$17,326
CorlanorIvabradine Hcl11$13,611
Bumetanide246$11,732
Mycophenolic AcidMycophenolate Sodium24$7,908
Tacrolimus37$6,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$6,439$21,368,6881,257 claims
AstraZenecaWainua, Farxiga$96,574$1,658,060321 claims
NovartisEntresto, Sandostatin Lar Depot$264$545,897423 claims
Boehringer IngelheimJardiance$81$398,076337 claims
Novo NordiskOzempic$372$108,935111 claims
AmgenCorlanor$85$13,61111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Kansason file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →